Edition:
United Kingdom

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

6.30USD
20 Apr 2018
Change (% chg)

$0.10 (+1.61%)
Prev Close
$6.20
Open
$6.25
Day's High
$6.60
Day's Low
$6.20
Volume
436,404
Avg. Vol
744,195
52-wk High
$10.65
52-wk Low
$1.50

Select another date:

Tue, Mar 27 2018

BRIEF-Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing

* SORRENTO THERAPEUTICS ANNOUNCES UNSECURED $120.5M CONVERTIBLE NOTE FINANCING

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 1.4 MILLION SHARES CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IFWs1n) Further company coverage:

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 34.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2pwUPvb) Further company coverage:

BRIEF-Sorrento Therapeutics Welcomes Jiong Shao As Chief Financial Officer

* SORRENTO THERAPEUTICS WELCOMES JIONG SHAO AS CHIEF FINANCIAL OFFICER AND REAFFIRMS INTENT TO SEEK NASDAQ/HKSE DUAL LISTING IN 2018

BRIEF-Sorrento Says Its CAR-T Cell Therapy Showed Therapeutic Activity In Stage IV Pancreas Cancer In Early Stage Trial

* SORRENTO THERAPEUTICS AUTOLOGOUS ANTI-CEA CAR-T CELL THERAPY FOR LIVER METASTASES DEMONSTRATES THERAPEUTIC ACTIVITY IN STAGE IV PANCREAS CANCER IN A PHASE 1B HITM-SURE TRIAL (NCT02850536) Source text for Eikon: Further company coverage:

FDA approves Sorrento's non-opioid painkiller patch, shares jump

Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year.

UPDATE 2-FDA approves Sorrento's non-opioid painkiller patch, shares jump

* To compete with Endo's Lidoderm, generics (Adds background, company and analyst comments)

BRIEF-Sorrento Therapeutics' Unit Receives FDA Approval For Non-Opioid Ztlido

* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN

FDA approves Sorrento's painkiller patch

Feb 28 The U.S. Food And Drug Administration on Wednesday approved Sorrento Therapeutics Inc's ZTlido, a stick-on patch to treat nerve pain due to shingles.

BRIEF-Sorrento Therapeutics- Audit Committee Concluded Co's Financial Statements For 3 & 9 Months Ended Sept 30, 2017 Should Not Be Relied Upon​

* SORRENTO THERAPEUTICS - ‍ON FEB 26, AUDIT COMMITTEE CONCLUDED CO'S FINANCIAL STATEMENTS FOR 3 & 9 MONTHS ENDED SEPT 30, 2017 SHOULD NOT BE RELIED UPON​

Select another date: